Comments
AstraZeneca Pharma India Ltd has launch antiplatelet drug Brilinta (Ticagrelor) in India.
Brilinta is an oral antiplatelet treatment for acute coronary syndromes in adult patients.
The company said the drug works by preventing the formation of new blood clots and maintaining blood flow in the body to help reduce patient’s risk of another cardiovascular event (called atherothrombotic events) such as heart attack or cardiovascular death.
The Drug Controller General of India, based on the New Drug Advisory Committee’s recommendations, granted its approval in May 2012 for marketing Brilinta (Ticagrelor) tablets in India.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.